

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS; AND (2) CONTINUED SUSPENSION OF TRADING

Reference is made to the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 April 2024, 18 April 2024, 5 June 2024, 27 June 2024, 28 June 2024, 31 July 2024, 30 September 2024, 4 October 2024 and 3 January 2025, 31 March 2025, 11 July 2025 and 14 July 2025 (collectively the “**Announcement(s)**”) in relation to, among others, the initial resumption guidance and additional resumption guidance imposed by the Stock Exchange on the Company (collectively, the “**Resumption Guidance**”) pursuant to, among other things, Rules 13.09(2)(a) and 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

UPDATE ON BUSINESS OPERATIONS

The Company is principally engaged in (i) the trading of footwear products; (ii) the trading of healthcare products; (iii) the provision of financial services; and (iv) the provision of online medical services. As at the date of this announcement and as further disclosed below, the Group’s business in the trading of healthcare products and the provision of financial services and online medical services is operating at a minimal level.

Reference is made to the Announcements of 3 January 2025 and 31 March 2025 in relation to quarterly update on resumption progress. The Company would like to provide updates on (i) the bankruptcy proceedings of Shangying Medical; and (ii) the recovery of the Loan by SY Health, as follows:

- (1) **Bankruptcy proceedings of Shangying Medical** — As Shangying Medical is currently insolvent, it is highly unlikely that its debts could be paid off by the auction of its assets. Hence, after completing the auction and/or disposal of Shangying Medical’s assets, the Administrator may apply to the relevant PRC Court to declare Shangying Medical bankrupt. Due to the uncertainty regarding the time required for the auction and/or disposal of Shangying Medical’s assets, the Administrator is currently unable to make a concrete assessment of the expected completion time of the bankruptcy proceedings.
- (2) **Recovery of the Loan by SY Health** — As previously announced, SY Health has, on 12 December 2024, issued a termination notice to Century Health in accordance with the Loan Deed and has engaged a legal adviser in the recovery of the Loan. Payment reminders and demand letters have been subsequently sent to Century Health and to the personal guarantors, namely Mr. Wenfei Yang (“**Mr. Yang**”) and Mr. Hao Ding. As at the date of this announcement, the Loan (together with all other amounts owing thereunder including accrued and unpaid interest) however remains outstanding. Meanwhile, the Company has commenced negotiating with Mr. Yang to come out with a repayment plan and schedule. Accordingly, it is expected that substantial part of the Loan will be settled by Century Health by the end of 2025, while the remaining balance of the Loan will be extended by way of entering into of an extension agreement subject to further negotiation between the parties.

Save as disclosed above, notwithstanding the suspension of trading in the Company’s shares, up to the date of this announcement, the Group is carrying on its business operations as usual in all material respects and will continue to assess and monitor its financial position and business operations. Nonetheless, in light of the financial difficulty currently faced by the Company, despite every effort has been made by the management of the Company to work closely with all relevant parties towards the publication of the outstanding financial results and hence the resumption of trading in the Company’s shares, the shortage of funds has inevitably impacted and delayed the relevant progress.

UPDATE ON PROGRESS OF RESUMPTION

The Board wishes to update the Shareholders and potential investors of the Company on the progress of the Company's resumption plan and fulfilment of the Resumption Guidance of the Stock Exchange as at the date of this announcement as summarised below:

Resumption Guidance

- (i) publish all outstanding financial results required under the Listing Rules and address any audit modifications

Update on resumption progress and the expected timeline

Reference is made to the Announcement dated 31 March 2025.

As at the date of this announcement, the auditor of the Company is still in the process of conducting the relevant audit procedures for the audit of 2023 Annual Results.

Based on information currently available, it is expected that the 2023 Annual Results, the 2024 Interim Results and the 2024 Annual Results would be published by the Company by or around 31 August 2025.

- (ii) demonstrate the Company's compliance with Rule 13.24

Since the suspension of trading in the Company's shares on 2 April 2024 and up to the date of this announcement, save as disclosed above, the business operations of the Group have operated as usual in all material respects.

The Company's compliance with Rule 13.24 of the Listing Rules would be assessed with the publication of the outstanding financial results.

- (iii) inform the market of all material information for the Shareholders and potential investors to appraise the Company's position

Since the suspension of trading in the Company's shares on 2 April 2024, the Company has kept the Shareholders and potential investors of the Company informed of all material information in relation to, among others, the Resumption Guidance and other relevant updates and progresses by way of announcements.

The Company will continue to keep the Shareholders and its potential investors informed of any relevant material developments by making further announcement(s) as and when appropriate in accordance with the requirements under the Listing Rules.

Resumption Guidance**Update on resumption progress and the expected timeline**

(iv) re-comply with Rules 3.10(1), 3.21, 3.05 and 13.92(2) of the Listing Rules

Reference is made to the Announcements dated 11 July 2025 and 14 July 2025, respectively.

Following the appointment of Mr. Li Liang, Ms. Huang Lin and Mr. Du Jianfeng as independent non-executive Directors and members of each of the Audit Committee, the Remuneration Committee and the Nomination Committee as well as the appointment of Mr. Zhang Ming Qi as an Authorised Representative, (i) there are at least three independent non-executive Directors on the Board; (ii) the Audit Committee comprises four members, all of whom are independent non-executive Directors; (iii) the Remuneration Committee comprises four members, all of whom are independent non-executive Directors; (iv) the Nomination Committee comprises four members, all of whom are independent non-executive Directors; (v) the Company has two Authorised Representatives; and (vi) the Board comprises directors of different genders.

Accordingly, the Company has re-complied with the requirements under Rules 3.10(1), 3.21, 3.05 and 13.92(2) of the Listing Rules as well as the requirements under the respective terms of reference of the Audit Committee, the Remuneration Committee and the Nomination Committee.

The expected timeline for publication of the outstanding financial results is indicative only and may or may not be updated depending on, among others, any additional audit procedures.

The Company will publish further announcement(s) on the status and development of the Company as and when appropriate, as well as announce quarterly updates on its development of the resumption status in accordance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024 and will remain suspended pending the fulfilment of the Resumption Guidance. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

The Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Non-executive Director

Hong Kong, 25 July 2025

As at the date of this announcement, the Board comprises four non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and four independent non-executive Directors, namely, Mr. Wang Jian, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.